Overview of Genetically Engineered Mouse Models of Colorectal Carcinoma to Enable Translational Biology and Drug Development

Jatin Roper1, Eric S. Martin2, Kenneth E. Hung1

1 Tufts Medical Center, Boston, Massachusetts, 2 Harvard Medical School, Boston, Massachusetts
Publication Name:  Current Protocols in Pharmacology
Unit Number:  Unit 14.29
DOI:  10.1002/0471141755.ph1429s65
Online Posting Date:  June, 2014
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library


Preclinical models for colorectal cancer (CRC) are critical for translational biology and drug development studies to characterize and treat this condition. Mouse models of human cancer are particularly popular because of their relatively low cost, short life span, and ease of use. Genetically engineered mouse models (GEMMs) of CRC are engineered from germline or somatic modification of critical tumor suppressor genes and/or oncogenes that drive mutations in human disease. Detailed in this overview are the salient features of several useful colorectal cancer GEMMs and their value as tools for translational biology and preclinical drug development. Curr. Protoc. Pharmacol. 65:14.29.1‐14.29.10. © 2014 by John Wiley & Sons, Inc.

Keywords: cancer models; genetically engineered mouse models; colorectal cancer; orthotopic transplantation

PDF or HTML at Wiley Online Library

Table of Contents

  • Introduction
  • ApcMin , a Germline Gemm of CRC
  • CRC Models Based on Cre ‐Mediated Recombination of Target Genes in the Intestine
  • Adeno‐ Cre Gemm of CRC
  • Carbonic Anhydrase‐1‐ Cre Gemm of CRC
  • Orthotopic Transplant Model of CRC
  • Conclusions
  • Literature Cited
  • Figures
  • Tables
PDF or HTML at Wiley Online Library


PDF or HTML at Wiley Online Library



Literature Cited

Literature Cited
   Benbrook, D.M. , Guruswamy, S. , Wang, Y. , Sun, Z. , Mohammed, A. , Zhang, Y. , Li, Q. , and Rao, C.V. 2013. Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity. Cancer Prev. Res. 6:908‐916.
   Boivin, G.P. , Washington, K. , Yang, K. , Ward, J.M. , Pretlow, T.P. , Russell, R. , Besselsen, D.G. , Godfrey, V.L. , Doetschman, T. , Dove, W.F. , Pitot, H.C. , Halberg, R.B. , Itzkowitz, S.H. , Groden, J. , and Coffey, R.J. 2003. Pathology of mouse models of intestinal cancer: Consensus report and recommendations. Gastroenterology 124:762‐777.
   Cancer Genome Atlas Network. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330‐337.
   Coffee, E.M. , Faber, A.C. , Roper, J. , Sinnamon, M.J. , Goel, G. , Keung, L. , Wang, W.V. , Vecchione, L. , de Vriendt, V. , Weinstein, B.J. , Bronson, R.T. , Tejpar, S. , Xavier, R.J. , Engelman, J.A. , Martin, E.S. , and Hung, K.E. 2013. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAFV600E colorectal cancer. Clin. Cancer Res. 19:2688‐2698.
   Corpet, D.E. and Pierre, F. 2003. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol. Biomark. Prev. 12:391‐400.
   Efeyan, A. and Sabatini, D.M. 2010. mTOR and cancer: many loops in one pathway. Curr. Opin. Cell Biol. 22:169‐176.
   Fujishita, T. , Aoki, K. , Lane, H.A. , Aoki, M. , and Taketo, M.M. 2008. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc. Natl. Acad. Sci. U.S.A. 105:13544‐13549.
   Hung, K.E. , Maricevich, M.A. , Richard, L.G. , Chen, W.Y. , Richardson, M.P. , Kunin, A. , Bronson, R.T. , Mahmood, U. , and Kucherlapati, R. 2010. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc. Natl. Acad. Sci. U.S.A. 107:1565‐1570.
   Hutchinson, L. and Kirk, R. 2011. High drug attrition rates — where are we going wrong? Nat. Rev. Clin. Oncol. 8:189‐190.
   Jemal, A. , Bray, F. , Center, M.M. , Ferlay, J. , Ward, E. , and Forman, D. 2011. Global cancer statistics. CA Cancer J. Clin. 61:69‐90.
   Johnson, L. , Greenbaum, D. , Cichowski, K. , Mercer, K. , Murphy, E. , Schmitt, E. , Bronson, R.T. , Umanoff, H. , Edelmann, W. , Kucherlapati, R. , and Jacks, T. 1997. K‐ras is an essential gene in the mouse with partial functional overlap with N‐ras. Genes Dev. 11:2468‐2481.
   Kandoth, C. , McLellan, M.D. , Vandin, F. , Ye, K. , Niu, B. , Lu, C. , Xie, M. , Zhang, Q. , McMichael, J.F. , Wyczalkowski, M.A. , Leiserson, M.D. , Miller, C.A. , Welch, J.S. , Walter, M.J. , Wendl, M.C. , Ley, T.J. , Wilson, R.K. , Raphael, B.J. , and Ding, L. 2013. Mutational landscape and significance across 12 major cancer types. Nature 502:333‐339.
   Martin, E.S. , Belmont, P.J. , Sinnamon, M.J. , Richard, L.G. , Yuan, J. , Coffee, E.M. , Roper, J. , Lee, L. , Heidari, P. , Lunt, S.Y. , Goel, G. , Ji, X. , Xie, Z. , Xie, T. , Lamb, J. , Weinrich, S.L. , VanArsdale, T. , Bronson, R.T. , Xavier, R.J. , Vander Heiden, M.G. , Kan, J.L. , Mahmood, U. , and Hung, K.E. 2013. Development of a colon cancer GEMM‐derived orthotopic transplant model for drug discovery and validation. Clin. Cancer Res. 19:2929‐2940.
   Moser, A.R. , Pitot, H.C. , and Dove, W.F. 1990. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247:322‐324.
   Roper, J. and Hung, K.E. 2012. Priceless GEMMs: Genetically engineered mouse models for colorectal cancer drug development. Trends Pharmacol. Sci. 33:449‐455.
   Roper, J. , Richardson, M.P. , Wang, W.V. , Richard, L.G. , Chen, W. , Coffee, E.M. , Sinnamon, M.J. , Lee, L. , Chen, P.‐C. , Bronson, R.T. , Martin, E.S. , and Hung, K.E. 2011. The dual PI3K/mTOR inhibitor NVP‐BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild‐type colorectal cancer. PloS One 6:e25132.
   Roth, A.D. , Tejpar, S. , Delorenzi, M. , Yan, P. , Fiocca, R. , Klingbiel, D. , Dietrich, D. , Biesmans, B. , Bodoky, G. , Barone, C. , Aranda, E. , Nordlinger, B. , Cisar, L. , Labianca, R. , Cunningham, D. , Van Cutsem, E. , and Bosman, F. 2010. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC‐3, EORTC 40993, SAKK 60‐00 trial. J. Clin. Oncol. 28:466‐474.
   Serebrennikova, O.B. , Tsatsanis, C. , Mao, C. , Gounaris, E. , Ren, W. , Siracusa, L.D. , Eliopoulos, A.G. , Khazaie, K. , and Tsichlis, P.N. 2012. Tpl2 ablation promotes intestinal inflammation and tumorigenesis in Apcmin mice by inhibiting IL‐10 secretion and regulatory T‐cell generation. Proc. Natl. Acad. Sci. U.S.A. 109:E1082‐E1091. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22451924 [Accessed March 28, 2012].
   Sharpless, N.E. and Depinho, R.A. 2006. The mighty mouse: Genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 5:741‐754.
   Shibata, H. , Toyama, K. , Shioya, H. , Ito, M. , Hirota, M. , Hasegawa, S. , Matsumoto, H. , Takano, H. , Akiyama, T. , Toyoshima, K. , Kanamaru, R. , Kanegae, Y. , Saito, I. , Nakamura, Y. , Shiba, K. , and Noda, T. 1997. Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science 278:120‐123.
   Taketo, M.M. and Edelmann, W. 2009. Mouse models of colon cancer. Gastroenterology 136:780‐798.
   Vogelstein, B. , Papadopoulos, N. , Velculescu, V.E. , Zhou, S. , Diaz, L.A. Jr , and Kinzler, K.W. 2013. Cancer genome landscapes. Science 339:1546‐1558.
   Washington, M.K. , Powell, A.E. , Sullivan, R. , Sundberg, J.P. , Wright, N. , Coffey, R.J. , and Dove, W.F. 2013. Pathology of rodent models of intestinal cancer: progress report and recommendations. Gastroenterology 144:705‐717.
   Wong, K.‐K. , Engelman, J.A. , and Cantley, L.C. 2010. Targeting the PI3K signaling pathway in cancer. Curr. Opin. Genet. Devel. 20:87‐90.
   Xue, Y. , Johnson, R. , Desmet, M. , Snyder, P.W. , and Fleet, J.C. 2010. Generation of a transgenic mouse for colorectal cancer research with intestinal cre expression limited to the large intestine. Mol. Cancer Res. 8:1095‐1104.
   Zigmond, E. , Halpern, Z. , Elinav, E. , Brazowski, E. , Jung, S. , and Varol, C. 2011. Utilization of murine colonoscopy for orthotopic implantation of colorectal cancer. PloS One 6:e28858.
PDF or HTML at Wiley Online Library